mAb Beta-27
An anti-SARS-CoV-2 monoclonal antibody.
General information
mAb Beta-27 is a monoclonal antibody neutralizing SARS-CoV-2 identified in a memory B cell of a COVID-19 convalescent patient who had been infected with the Beta variant of SARS-CoV-2. It was shown to protect mice in a viral challenge (prevention of weight loss and decrease of viral titres) (Liu et al., 2022). The antibody neutralized the Delta strain, as well, but acted only weakly against the Omicron strain (Dejnirattisai et al., 2022).
Synonyms
mAb β27
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Spike protein Spike variant Cryo-EM Crystallization Novel compound Biophysical assay Protein factor Animal model In vitro Mechanism Antibody Screening |
in vitro biophysical assay; crystallization; cryo-EM; plasma of COVID-19 (Beta strain) convalescent patients; Vero cells; VeroE6/TMPRSS2 cells; Vero-hACE2-TMPRSS2 cells; K18-hACE C57BL/6J mice; SARS-CoV-2 (various strains) | 21.02 | Neutralizes the Beta variant of SARS-CoV-2 in vitro. It was shown to protect mice in a viral challenge (prevention of weight loss and decrease of viral titres). |
Nov/27/2021 |
